Savara (SVRA) Price & Analysis

Compare

1,192 Followers

SVRA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.89 - $4.70

Previous CloseN/A

Volume189.20K

Average Volume (3M)1.25M

Market Cap

$572.09M

Enterprise Value$376.76M

Total Cash (Recent Filing)$146.44M

Total Debt (Recent Filing)$29.65M

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Nov 06, 2025

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding172,836,930

10 Day Avg. Volume1,959,874

30 Day Avg. Volume1,245,887

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue1.39K

Enterprise Value/Gross Profit-5.02K

Enterprise Value/Ebitda-3.24

Forecast

1Y Price Target

$5.25

Price Target Upside60.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Market PositionMolbreevi stands to become the first and only approved therapy in the aPAP space, indicating a unique market position.

Regulatory ProgressThe company has reached alignment with the FDA following a Type A meeting on the Chemistry, Manufacturing, and Controls (CMC) data needed to resubmit the BLA.

Bears Say

Management ConfidenceConcerns arise because Savara management has not conveyed confidence that past mistakes will not be repeated, especially with ongoing dialogue with the FDA.

Regulatory UncertaintyThere is uncertainty over whether the FDA will call an AdCom for Molbreevi, which could affect both the timeline and the focus of the review.

Savara News

3 Best Stocks to Buy Now, 8/22/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

7d ago

COP

INTU

Closing Bell Movers: Nordson up 5% after Q3 earnings beat

In the opening hour of the evening session, U.S. equity futures are little changed following more losses in...

9d ago

Savara publishes IMPALA-2 clinical trial results in NEJM

Savara (SVRA) announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in...

9d ago

SVRA

H.C. Wainwright upgrades Savara to Buy on resubmission prospects

H.C. Wainwright analyst Andrew Fein upgraded Savara (SVRA) to Buy from Neutral with a price target of $5,...

14d ago

SVRA

Savara upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Savara (SVRA) to Buy from Neutral with a $5 price target Published first on TheFly...

14d ago

SVRA

Savara price target raised to $6 from $5 at Oppenheimer

Oppenheimer raised the firm’s price target on Savara (SVRA) to $6 from $5 and keeps an Outperform rating...

14d ago

SVRA

Savara reports Q2 EPS (14c), consensus (12c)

“Following a recent Type A meeting with the FDA, and receipt of the meeting minutes, we believe we...

16d ago

SVRA

Savara Inc. Reports Increased Loss Amid Ongoing R&D Investments

Savara ( ($SVRA) ) has released its Q2 earnings. Here is a breakdown of the information Savara presented...

15d ago

SVRA

Savara Re-elects Board Members at Annual Meeting

Savara ( ($SVRA) ) has provided an announcement. On June 5, 2025, Savara Inc. held its annual stockholders...

3M ago

SVRA

Savara assumed with an Outperform at Oppenheimer

Oppenheimer assumed coverage of Savara (SVRA) with an Outperform rating with a price target of $5, down from...

3M ago

SVRA

Savara downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Savara (SVRA) to Neutral from Buy with a price target of $2, down from $6,...

3M ago

SVRA

Savara price target lowered to $2 from $3 at Evercore ISI

Evercore ISI lowered the firm’s price target on Savara (SVRA) to $2 from $3 and keeps an In...

3M ago

SVRA

Savara price target lowered to $8 from $9 at Guggenheim

Guggenheim analyst Vamil Divan lowered the firm’s price target on Savara (SVRA) to $8 from $9 and keeps...

3M ago

SVRA

Savara Faces FDA Setback for MOLBREEVI Application

Savara ( ($SVRA) ) has issued an announcement. On May 27, 2025, Savara Inc. announced it received a...

3M ago

SVRA

SVRA FAQ

What was Savara’s price range in the past 12 months?

Savara lowest stock price was $1.89 and its highest was $4.70 in the past 12 months.

What is Savara’s market cap?

Savara’s market cap is $572.09M.

When is Savara’s upcoming earnings report date?

Savara’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.

How were Savara’s earnings last quarter?

Savara released its earnings results on Aug 13, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.02.

Is Savara overvalued?

According to Wall Street analysts Savara’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Savara pay dividends?

Savara does not currently pay dividends.

What is Savara’s EPS estimate?

Savara’s EPS estimate is -0.13.

How many shares outstanding does Savara have?

Savara has 172,836,930 shares outstanding.

What happened to Savara’s price movement after its last earnings report?

Savara reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went up 4.651%.

Which hedge fund is a major shareholder of Savara?

Currently, no hedge funds are holding shares in SVRA

Savara Stock Smart Score

Neutral

Fundamentals

Return on Equity

-99.30%

Trailing 12-Months

Asset Growth

17.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Savara

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Savara (SVRA) Earnings & Revenues

Historic Earnings Reports

SVRA Stock 12 Month Forecast

Average Price Target

$5.25

▲(60.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","9":"$9"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3,5,7,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,3.006153846153846,3.422307692307692,3.838461538461538,4.254615384615384,4.670769230769231,5.086923076923076,5.503076923076923,5.919230769230769,6.335384615384616,6.751538461538462,7.167692307692308,7.583846153846154,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,2.7946153846153843,2.999230769230769,3.2038461538461536,3.4084615384615384,3.613076923076923,3.8176923076923073,4.022307692307692,4.226923076923077,4.431538461538461,4.636153846153846,4.840769230769231,5.045384615384615,{"y":5.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.59,2.5446153846153843,2.499230769230769,2.4538461538461536,2.4084615384615384,2.363076923076923,2.3176923076923077,2.272307692307692,2.226923076923077,2.1815384615384614,2.1361538461538463,2.0907692307692307,2.0453846153846156,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.95,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.54,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.27,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >